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Purpose: Lung cancer (LC) and its treatment impose a significant burden on patients’
life. However, patient-centered outcomes are rarely collected during patient follow-up.
Filling this gap, the International Consortium for Health Outcomes Measurement (ICHOM)
developed a standard set of variables for newly diagnosed LC patients. In order to
facilitate the use of this standard set, the project aims to adapt it to the Spanish setting.
Methods: The variables (instrument and periodicity) to be included in Spanish standard
set were selected through consensus during 4 nominal groups (13 oncologists, 14
hospital pharmacists, 4 hospital managers and 3 LC patients), under the supervision of
a Scientific Committee (1 oncologist, 3 hospital pharmacists, 2 LC patients advocates).
Results: The variables agreed upon included: (1) case-mix: demographic [age, sex,
education and social-family support], clinical [weight loss, smoking status, comorbidities
(Charlson index), pulmonary function (FEV-1)], tumor [histology, clinical, and pathological
stage (TNM), EGFR, ALK, ROS-1, PD-L1] and treatment factors [intent and completion]
and (2) outcomes: degree of health [performance status (ECOG) and quality-of-life
(EQ-5D, LCSS)], survival [overall survival and cause of death], quality of death [place
of death, end-of-life care and palliative care, death aligned with living will], treatment
complications, and others [date of diagnosis and treatment initiation, productivity loss
(sick leave)].
Conclusion: The adaptation of ICHOM standard set to the Spanish setting pave the
way to standardize the collection of variables in LC.
Keywords: lung cancer, patient-centered care, outcome measurement, patient-reported outcomes, patient
centricity, quality of life, standard set, ICHOM
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INTRODUCTION
In Spain, 28,645 new cases of lung cancer (LC) are diagnosed each
year, representing the leading cause of cancer-related mortality
(1). LC shows a heterogeneous histology and genetic profile,
with non-small-cell LC (NSCLC) being the most frequent (2).
The management of the disease is challenging and the choice of
the optimal treatment is based on several factors, including the
histology, tumor stage at diagnosis and patient’s comorbidities
and performance status (3, 4).
Despite the significant advances in LC management over the
last decade, the disease still impose a significant psychological,
emotional, and financial burden on patients (5–7). Disease
symptoms such as fatigue, loss of appetite, shortness of breath,
cough and pain have been identified as significant predictors
of poor health related quality of life (HRQoL) (8, 9). Of note,
systematic weekly collection of LC associated symptoms has been
related to higher survival (10–13), better HRQoL and a better
allocation of health resources (12).
Despite PROs relevance, their systematic collection using
standardized and validated instruments is mostly limited to
the clinical research setting. Standardization of health outcomes
measurements, both clinical and PROs, in routine clinical
practice is key to ensure an effective and efficient healthcare
provision. In fact, experience gained from other fields shows that
the systematic and standardized collection of outcomes is the sine
qua non to improve the quality of any process (14).
The International Consortium for Health Outcomes
Measurements (ICHOM) (15) is a non-profit organization
that has carried out several initiatives to attain this required
standardization. All standard sets developed by ICHOM
share hallmark features: (a) outcomes variables are defined
according to the pathology; (b) they represent the minimum
set of relevant outcomes from both healthcare professional and
patient perspective; (c) patients are involved in the standard
set development; (d) they include PROs; (e) their methods of
measurement and measurement frequency are well-defined to
ensure benchmarking.
A standard set of patient-centered outcomes for LC (16) was
designed by ICHOM for all patients with newly diagnosed LC,
including NSCLC and small cell LC (SCLC), independently of
the treatment received (surgery, radiotherapy, chemotherapy,
targeted therapy and immunotherapy, palliative care). The set
consists of two categories of variable: case-mix and outcomes.
The former includes baseline sociodemographic, clinical and
tumor-related variables. The latter reflects aspects related to the
degree of health (including HRQoL), survival, quality of death,
treatment complications as well as others like time from diagnosis
to treatment.
The long-term goal of ICHOM initiatives is to develop a
series of standard sets of variables to promote the consistency
in data collection among different institutions within the same
country or different countries. However, when implementing
such standard sets, different aspects need to be considered: (1)
doctors and patients should be familiarized with the variables
included in the set; (2) the technology and instruments needed to
measure the selected variables should be available; (3) the target
population should be defined according to each country’s clinical
needs. In this light, the main objective of the present study was
to adapt the ICHOM standard set of health outcomes for patients
with LC in the Spanish setting.
MATERIALS AND METHODS
A scientific committee, consisting of an oncologist specialized in
LC (AC), three hospital pharmacists (VE-V, BM-A, RC-B.) and
two patient advocates (BG, BB), led and coordinated the project.
The project comprised four phases: (1) literature review; (2)
first scientific committee meeting; (3) four nominal groups; (4)
second scientific committee meeting.
Literature Review
An update of the literature search conducted by ICHOM (16) was
carried out in Medline/PubMed. The objective of the literature
review was to identify health outcomes (clinical and PROs),
the instruments to measure them, as well as, the frequency of
measurement to be used during LC patients’ follow-up. Clinical
trials or systematic reviews in English and/or Spanish published
between 01/01/2015 and 31/12/2017 were included in the review.
Search terms and strategy are shown in Supplementary Table 1.
First Scientific Committee Meeting
A group discussion was held with the members of the scientific
committee to define the variables to be presented and evaluated
in the nominal groups. According to this purpose, all variables
included in the ICHOM standard set (Table 1) as well as those
identified through the updated literature review (Table 2) were
screened by the scientific committee.
Nominal Group Meetings
The aim of the nominal groups was to reach consensus on the
variables to ultimately be included in the standard set of health
outcomes for LC in Spain as well as to define the measurement
instrument and frequency of measurement to be used.
Nominal group is a qualitative methodology which allows
to achieve consensus, while assuring a balanced participation
among group members that are given equal opportunity to
share their opinion (17). The methodology involves five steps
tailored to meet the purpose of the meeting as follows (18): (1)
Introduction and explanation: welcoming and explanation of the
purpose and procedure of the meeting; (2) Silent generation of
ideas: each participant evaluated individually (without consulting
or discussing with others) the variables proposed; (3) Sharing
ideas: participants shared individually the variables they had
selected; (4) Group discussion: participants could seek verbal
explanation or further details about any of the variables that
other participants had proposed; (5) Voting and ranking: during
this phase, participants were asked to prioritize the variables
proposed. Variables were included if≥75% of participants agreed
on their inclusion.
In order to be representative at a national level, four
nominal groups were conducted, involving experts from
different Spanish geographic areas. In each nominal group,
participation was limited to a maximum of 12 experts,
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TABLE 1 | ICHOM standard set (16).
Case mix variables
Demographic factors Baseline clinical factors Baseline tumor factors Treatment factors
- Age - Weight loss - Histology - Treatment intent
- Sex - Smoking status
- (never-smoker, ex-smoker, current smoker)
- Clinical stage - Completed treatment
- Ethnicity - Comorbidities (modified SCQ) - Pathological stage
- Educational level - Patient-reported health status (EORTC
QLC-C30 and EORTC QLC-LC13)
- EGFR mutation
- Performance status (ECOG) - ALK translocation
- Pulmonary function (FEV1 )
Outcomes variables
Degree of health Survival Quality of death Acute complications of
treatment
Other
- Performance status (ECOG) - Cause of death - Place of death - Major surgical complications - Time from diagnosis
to treatment
- Global health status (social functioning, physical
functioning, emotional functioning cognitive
function) (EORTC QLC-C30)
- Overall survival - Duration of time spent in










- Dyspnea and cough (EORTC QLC-LC13)
SCQ, Self-administered Comorbidity Questionnaire; EORTC, European Organization for Research and Treatment of Cancer; QLC-C30, core quality of life questionnaire; LC13, lung
cancer-specific quality of life questionnaire; ECOG, Eastern Cooperative Oncology Group; FEV1, forced expiratory volume; ALK, Anaplastic Lymphoma Kinase; EGFR, Epidermal growth
Factor Receptor; CTCAE, Common Terminology Criteria for Adverse Events.
including oncologists, hospital pharmacists, hospital managers,
and patient representatives. Participants of the nominal groups
were identified by the scientific committee, in collaboration with
patient advocacy groups (Asociación Española de afectados de
Cáncer de Pulmón [AEACaP] and Grupo Español de Pacientes
con Cáncer [GEPAC]), and the study coordinator. The selection
was based on the participant experience in LCmanagement, PRO
measurement as well as scientific contributions, availability, and
interest in the project.
Second Scientific Committee Meeting
A group discussion was carried out to review the results
obtained during the four nominal groups, and to determine the
inclusion/exclusion of those variables for which a consensus was
not reached during themeetings. Consensus was reached if≥75%
of the members of the scientific committee agreed on the variable
inclusion/exclusion. Based on the meeting results, the variables




The database search yielded 260 references, while 8 additional
publications were identified by hand-searching. A total of 128
publications were excluded by title and abstract. The full texts
of the remaining 140 articles were assessed for eligibility. All of
them were included in the qualitative synthesis and reviewed
to identify variables, and the respective measuring instruments,
that might have not been identified in the review conducted by
ICHOM. A flow diagram of the selection process according to
the PRISMA Guidelines is depicted in Figure 1.
Following publication screening, a total of 14 variables (6 case-
mix and 8 outcomes variables) and 6measuring instruments, that
had not been included in the ICHOM catalog, were identified
(Table 2).
First Scientific Committee Meeting
Through the review of the variables included in the ICHOM
standard set (Table 1) as well as those identified through the
updated literature review (Table 2), a total of 17 case-mix and
25 outcomes variables were selected by the scientific committee
to be presented and evaluated during the nominal groups.
Selected variables, together with their measuring instruments are
presented in Supplementary Tables 2, 3. During the meeting,
the scope of the standard set was also defined. In line with
the ICHOM standard set for LC, the target population of the
standard set defined within the present project framework was
set to include all patients with newly diagnosed LC, regardless of
the disease stage, type or therapeutic options.
Nominal Group Meetings
Overall, 13 oncologists, 14 hospital pharmacists, 4 hospital
managers and 3 LC patients participated in the nominal
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TABLE 2 | Variables and instruments identified in the literature review.
Case mix variables




- Children at home
- Number of organs
involved
- PD-L1 expression






Survival Disease control Quality of death
- Disease free survival
- Time to progression





- Aggressiveness of health
care
Measuring instruments
- CCI: to assess comorbidities
- SF-36 questionnaire: to assess health related quality of life
- HADS: to assess anxiety and depression.
- MSAS-SF: tomeasure the frequency, severity, and distress associated with,
32 separate, multidimensional symptoms experienced by patients.
- RECIST v.1.1 criteria: to assess tumor response
- Earle criteria: to assess the aggressiveness of health care
CCI, Charlson Comorbidity Index; CEA, Carcinoembryonic Antigen; CYFRA 21-1,
Cytokeratin 19 fragment; ERCC1, Excision Repair Cross-Complementation Group
1; HADS, Hospital Anxiety and Depression Scale; MSAS-SF, Memorial Symptom
Assessment Scale-Short Form; PD-L1, Programmed Death-Ligand 1; RRM1, Regulatory
Subunit of Ribonucleotide Reductase 1; SF-36, Short-Form 36.
group meetings. Thirty-five case-mix variables and 45 outcomes
variables were proposed during the meetings. Nevertheless,
consensus was only achieved for 13 case-mix (n= 2 demographic
factors, n = 3 baseline clinical factors, n = 7 baseline tumor
factors and n = 1 treatment factors) and six outcomes variables
across the four nominal groups (Supplementary Tables 2, 3).
Second Scientific Committee Meeting
Based on the results achieved during the nominal group
meetings, the scientific committee identified the variables to be
included in the standardized set of health outcomes for LC. The
variables finally included in the standard set are presented below.
Case-Mix Variables (Table 3)
Case-mix variables include those that allow patient
characterization. Assessment of these variables should be carried
out in the first visit after diagnosis, prior to treatment initiation.
In addition to the sociodemographic variables included in the
original ICHOM standard set (age and gender), it was agreed
to collect the family support, as it may reflect the patient’s
family environment, as well as, the degree of patient dependence.
Even though consensus was not reached among the nominal
groups about whether to include educational level as a case
mix variable, the scientific committee considered appropriate to
include it as a surrogate measurement of socioeconomic status.
This decision was motivated by previous studies showing a
relationship between educational level and patient prognosis (19,
20). Conversely, despite ICHOM recommendation, collection of
ethnicity data was considered not relevant to the Spanish setting,
and was, therefore, excluded from the set.
Aligned with the ICHOM recommendations, it was agreed
to gather data regarding the following baseline clinical factors:
unintentional weight loss, smoking status, comorbidities,
performance status and patient’s HRQoL. In addition, due to its
prognostic value, assessment of pulmonary function, through
the measurement of forced expiratory volume (FEV-1), was also
included in the set.
Consensus was reached on the use of Charlson Comorbidity
Index (21) to collect the comorbidities. Experts discouraged the
use of the questionnaire suggested by ICHOM, the Modified
Self-administered Comorbidity Questionnaire (22) for two
main reasons. First, a Spanish translation and validation of
the questionnaire is not currently available. Second, experts
considered that self-reporting of comorbidities may lead to
underestimating of the comorbidities perceived by patients as
irrelevant or unknown.
To assess patients’ performance status, experts agreed on the
use of the Eastern Cooperative Oncology Group (ECOG) scale.
This scale describes a patient’s level of functioning in terms of
self-care, carrying out daily activities, and physical ability (23).
The ICHOM proposed instruments to measure patient-
reported health status [EORTC-QLQ-C30 (24) and the LC
specific version QLQ-LC13 (25)] were not deemed appropriate
in the Spanish setting, as they are burdensome to complete
and their use is limited in routine clinical practice. Instead,
consensus was reached to use the generic questionnaire EuroQol
EQ-5D (26, 27), that is currently widely used in the Spanish
setting, and the LC specific questionnaire Lung Cancer Symptom
Scale (LCSS) (28), for which a Spanish validated version is
already available. The combined use of both questionnaires
allows to gather information about patient perspective on their
physical and emotional functioning, fatigue, vitality, pain, cough,
breathing difficulty, hemoptysis, and loss of appetite.
The clinical and pathological stage, defined by the TNM
staging scale, tumor histology and basis of diagnosis (clinical,
histological, or cytological), were identified as key variables to be
recorded as a case-mix variable.
Consensus was reached on including LC predictive
biomarkers such as EGFR gene mutational status, ALK
gene translocation, ROS-1 rearrangement and PD-L1 expression.
Due to the continuous advances on the molecular mechanisms
of LC, it was agreed to annually evaluate and update the list of
biomarkers to be included in the standard set.
Regarding patient treatment, it was agreed to collect data
on treatment intention (curative vs. palliative) and whether
treatment was completed (with or without dose reduction)




LC is associated with high mortality rates (1). Thus, overall
survival was considered a key variable to be included in the
standard set for patient’s follow up.Moreover, participants agreed
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FIGURE 1 | PRISMA Flow diagram.
on gathering information regarding the cause of death, indicating
whether it was tumor or treatment related. Conversely, following
ICHOM recommendations, progression-free survival (PFS) was
excluded from the standard set. Although PFS is commonly
assessed in most clinical trials as a measure of disease control, it
was considered potentially unreliable due to ascertainment bias
and, ultimately, less important than overall survival.
Complications of treatment
In line with ICHOM classification, treatment complications were
divided to surgery-related or associated with systemic therapy
and/or radiotherapy. Participants agreed on monitoring surgery-
related complications using the Observatorio de Resultados del
Servicio Madrileño de Salud (Outcomes Observatory of Madrid
Healthcare Services) classification. This classification includes
the reporting of whether the patient: (1) suffers a secondary
complication related to surgical care, (2) requires an urgent re-
admission for a cause related to surgical treatment in the first
7 days following discharge, or (3) dies in the first 30 days after
surgery (29).
In regard to the complications of systemic therapy and/or
radiotherapy, participants emphasized the importance of both
patient self-reporting and clinician reporting of adverse events.
Therefore, a consensus was reached to collect all grade 3 or higher
adverse events using both the Common Terminology Criteria
for Adverse Events (CTCAE) and Patient-Reported Outcomes
version of the CTCAE (PRO-CTCAE). Although the use of such
instruments might be time-consuming, participants agreed that
a standardized collection of treatment toxicities is necessary to
avoid the risk of overlooking important complications, and to
ensure their inclusion in the medical record.
Degree of health
HRQoL and performance status are frequently impaired in
LC patients (5, 8). Therefore, and in line with ICHOM
recommendations, it was agreed to collect both variables at
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TABLE 3 | Spanish standard set of patient-centered outcomes in LC.
Patient profile Variable Supporting information Measurement instrument Timing Data sources
Demographic factors
All patients Age Date of birth Baseline (before
treatment begins)
Clinical
Gender F: female; M: male Clinical
Family support Degree of family support and
degree of patient dependence
Yes/No Patient-reported
Educational level Level of schooling completed (0) Without studies; (1) primary school level; (2)
secondary school level; (3) higher education
Patient-reported
Baseline clinical factors
All patients Unintentional weight
loss
Yes/No/I don’t know Baseline (before
treatment begins)
Patient-reported
Smoking status Smoking status at diagnosis Pack-year index + smoking status
classification: Never-smoker (<100 cigarettes
in lifetime), ex-smoker (stopped >1 year before
diagnosis), current smoker
Patient-reported
Performance status ECOG scale Clinical
Patient-reported health
status
Tracked via generic questionnaire EQ5D and
LC specific questionnaire LCSS
Patient-reported
Comorbidities Charlson index Clinical
Pulmonary function FEV1 NA Clinical
Baseline tumor factors
All patients Clinical stage TNM scale Baseline (before
treatment begin)
Clinical
Pathological stage TNM scale Clinical
Histology NA Clinical
EGFR mutation* Yes/No/undetermined Clinical
ALK translocation* Yes/No/undetermined Clinical
ROS-1 rearrangement * Yes/No/undetermined Clinical
PD-L1 expression* Yes/No/undetermined Clinical
Treatment factors
All patients Treatment intent (1) curative; (2) palliative Baseline (before
treatment begins)
Physician-reported
Completed treatment (1) Yes, with dose reduction; (2) No, due to
toxicity; (3) No, due to patient’s will; (4) No, due
to patient’s death
At treatment ending Physician-reported
Case-mix variables.
NA, not applicable; ECOG, Eastern Cooperative Oncology Group; EQ-5D, EuroQol; LCSS, Lung Cancer Symptoms Scale; FEV-1, forced expiratory volume; EGFR, Epidermal growth
Factor Receptor; ALK, Anaplastic Lymphoma Kinase; PD-L1, Programmed Death-ligand; *List of Biomarkers annually valuated and updated.
baseline and during patients’ follow up. As previously indicated,
ECOG scale (23) was selected to assess patients’ performance
status, while the EQ-5D (26, 27) and LCSS questionnaire (28)
were chosen for the assessment of patients’ HRQoL.
Quality of death (end of life care)
Ensuring an adequate quality of end-of-life care as well as the
respect of patients’ wills has become a key healthcare objective
(30). Therefore, besides capturing place of death, participants
stressed the importance of assessing the alignment between the
care received at the end of life and patients’ living will. For this
purpose, it was agreed to register whether patients had a living
will, received aggressive care, and had access to palliative care in
the last 30 days of life, using Earle Criteria adapted for individual
patient use (Table 4). Earle Criteria evaluate quality of end of life
care by assessing: (a) administration of new anticancer therapies
or continuation of ongoing treatments very near death, (b)
number of emergency room visits, inpatient hospital admissions
or intensive care unit days near the end of life and (c) inadequate
access to palliative care and/or enrollment in hospice (31).
Others
Experts agreed to report both the date of diagnosis and the
time interval from diagnosis to treatment. Patient’s and/or
caregiver’s working life might be substantially influenced by
both the disease and treatment, causing potential situations of
absenteeism, presentism, or sick leave. In this light, experts
agreed to report patient’s and/or caregiver’s productivity loss, by
collecting sick leave or occupational disability for both patients
and caregivers.
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TABLE 4 | Spanish standard set of patient-centered outcomes in LC.
Patient profile Measure Supporting information Measurement instrument Timing Data sources
Degree of Health
All patients Performance status ECOG scale During follow-up visits Clinical
Patient-reported health
status
Global health status, physical
and emotional function
Tracked via generic
questionnaire EQ5D and LC
specific questionnaire LCSS
At 3, 6, and 12 months.
Later, tracked annually for
life*
Patient-reported
Fatigue, vitality, pain, cough,
difficulty breathing, hemoptysis
and loss of appetite
Tracked via LC specific
questionnaire LCSS
Survival
All patients Overall survival Date of death NA Administrative data
(death registry)
Cause of death Tumor/treatment related or not NA Clinical
Quality of death




Earle criteria: (1) patient receives chemotherapy or other
antineoplastic therapy in last 14 days of life; (2) patient
initiates a new therapeutic scheme in the last month of
life; (3) patient goes to emergency room more than once
in the last month of life or ICU admitted; (4) patient dies
at an oncology unit instead of receiving palliative care; (5)
patient does not receive palliative care before passing
away; (6) patient dies while receiving palliative care in the
last 72 h before hospital admission
30 days before death Clinical
Existence or doctor’s
knowledge about the
living will of patients
Yes/No NA Patient-reported





(1) Secondary complication related to surgical care; (2)
Urgent re-admission after the next 7 days
post-discharge, for a cause related to surgical treatment;









Presence of grade ≥3 CTCAETM NA Clinical
PRO- CTCAETM NA Patient reported
Others
All patients Time from diagnosis Date of hospital admission or
non-hospital consultation
when data of the histological
or cytological confirmation is
unknown
At diagnosis Clinical
Time from diagnosis to
treatment
NA When treatment begins Clinical
Patient productivity loss Sick leave or disability Yes/No NA Patient reported
Outcomes variables.
NA, not applicable; ECOG, Eastern Cooperative Oncology Group; EQ-5D, EuroQol; LCSS, Lung Cancer Symptoms Scale; *when treatment is change, Patient-reported health status
will be evaluated at 3, 6 and 12 months; CTCAE, Common Terminology Criteria for Adverse events; PRO-CTCAE, Patient-Reported Outcomes version of the CTCAE.
DISCUSSION
In clinical practice, measurement of outcomes that matter to
LC patients, aside from survival, remains limited. However,
to promote patient-centered care, the collection of outcomes
based on the patient’s priorities is crucial. Experience from the
implementation of ICHOM standard sets in clinical practice,
in diseases such as hip and knee osteoarthritis (32), cleft lip
and palate (33), coronary artery disease (34) or Parkinson’s
Disease (35), has shown a positive impact on all phases of
the care process. Likewise, a one-year pilot study conducted in
Netherlands demonstrated that the ICHOM standard set can
be implemented during routine lung cancer treatment without
significantly disturbing the routine workflow (36, 37). The
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authors concluded that the collection of PROs is not too time-
consuming, however it requires ad hoc tools and dedicated staff
(36, 37).
Patient information collated via PRO measures (PROMs)
allows clinicians to explore the perspective of the patients on
different aspects of the disease, during the follow-up.
This, in turn, promote a better involvement of the patient in
disease management (32–35). Moreover, PROMs use provides
the opportunity for patients to engage in their consultation in
advance, increasing self-awareness of their health and helping
them to tailor the consultation to their needs (32–35). Of
note, healthcare professionals also perceive the use of these
standard sets as a valuable tool that facilitates benchmarking.
Indeed, clinicians can learn from the outcomes data they gather
and, at the same time, share their knowledge and learn from
the experience of other healthcare professionals in different
settings (32–35).
Adaptation of the ICHOM standard set for LC to the Spanish
setting are essential steps in order to allow its implementation in
routine clinical practice since it allows to identify those variables
and its instruments, proposed by ICHOM that (1) are routinely
collected in Spanish clinical practice and/or Spanish clinicians
and patients are familiarized with; (2) the technology needed
to measure them is available in the Spanish setting; and (3)
the instruments to collect them are available and validated in
Spanish language.
In this regard, several of the PROMs proposed by ICHOM
have either not yet been validated or have had limited use in the
Spanish context, thus hindering their use in daily practice. Thus,
although divergence from the original standard set developed by
ICHOM might partly complicate international benchmarking of
LC patients’ outcomes, selecting the most suitable PROMs to our
setting is essential to ensure their use.
This standard set reflects the opinion of a group of 35 experts
on the management of LC and 5 patient representatives. Since
one of the main purposes of the standard set is to reflect
outcomes that matter to patients, their broad participation in
the project is one of its main strengths. Patient representatives
have been actively involved in the decision-making process
as members of the scientific committee or participants in the
nominal groups. Although no major differences are expected,
it is important to highlight that different groups of experts
and patients could have agreed on different recommendations.
In order to minimize this potential bias, and ensure national
representativeness, participants from four broad geographic
areas were involved in the project.
It must be acknowledged that the update of the literature
review, on which the present standard set is based, covers
studies published until 31/12/2017. Thus, some relevant variables
(e.g., the determination of recently identified LC related
biomarkers) may have not been considered when elaborating
the standard set. To minimize this limitation, and due to
the continuing advances in both the knowledge and treatment
of this disease, we recommend to periodically update the
list of biomarkers to evaluate during patient follow-up. In
addition, we also suggest that the present standard set be
periodically updated.
Of note, the present adaptation of the ICHOM standard set
for LC represents a starting point, and several barriers need
to be addressed on the road to its successful implementation
in the Spanish setting. Namely, the time required for the
collection of the variables proposed, the lack of digital tools
allowing a systematic and automatic PROMs compilation,
together with a limited education and information of patients
and clinicians about PROMs, have been identified as the main
barriers to the implementation of the present standard set
(38). Newer platforms for data collection, based on information
and communication technologies, may reduce both patient and
clinician burden, as well as, data processing time, thus facilitating
the use or PROMS in clinical practice (39). Other barriers to
be tackled to ensure widespread use of this standard set are
inherent to the structure of the Spanish national healthcare
system (SNHS). Indeed, one of the main characteristics of the
SNHS is its heterogeneity: healthcare processes, organizational
models as well as information systems differ widely both
among and within regions. This heterogeneity has been also
observed in the context of LC, with a recent study showing
remarkable differences among Spanish regions in the provision
of care for LC patients (40). Overall, these data indicate
the need to promote harmonization of the best practice in
LC management and treatment to guarantee the success of
this initiative.
Besides addressing the aforementioned barriers, a further
step to test the feasibility and promote the integration of
the defined standard set into the Spanish healthcare model
may involve the conduction of a pilot implementation study.
Indeed, due to the heterogeneity of SNHS, a pilot study is
key to determine the feasibility and viability of introducing
the standard set in routine clinical practice. The results of
the pilot study may provide insights into the main resource
requirements and organizational challenges to be tackled during
the implementation.
Although data from Standard Set implementation is
limited, previous experiences suggest that several requirements
are needed to ensure its implementation in a particular
setting: (1) appropriate staff to support the implementation
of PROMs tools, facilitate ongoing data collection, and
maximize the completeness of data collection and, (2)
adequate technology to support for database/platform
development. Moreover, during the implementation process
the knowledge of existing workflows for patient assessment
and review, and the patient’s journey in the hospital system
is crucial.
CONCLUSION
The present adaptation of ICHOM standard set may
facilitate its implementation in Spanish clinical practice,
paving the way to standardize the collection of variables
in LC, and promoting the incorporation of patients’
perspective in LC management. In turn, the information
provided through the systematic compilation of this set of
variables may allow both clinicians and health policy makers
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to define strategies aimed at achieving high-quality and
patient-centered care.
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